Wolfe Research Begins Coverage on Palisade Bio (NASDAQ:PALI)

Key Points

• Wolfe Research initiated coverage with an "outperform" rating and a $7.00 price target, implying about a 274% upside from the stock's prior close.
• Analyst views are mixed—one Strong Buy, six Buy and one Sell—resulting in an average rating of "Moderate Buy" and an average target price of $10.20.
• Palisade Bio trades around $1.87 with a market cap of about $310M (52‑week range $0.53–$2.64) and is a clinical‑stage biotech whose lead candidate, PDS0108, is an intratumoral TLR9 agonist currently in Phase 1/2 trials.

Wolfe Research assumed coverage on shares of Palisade Bio (NASDAQ:PALI - Get Free Report) in a research note issued on Thursday. The firm set an "outperform" rating and a $7.00 price target on the stock. Wolfe Research's price objective suggests a potential upside of 274.33% from the stock's previous close.

A number of other equities research analysts have also weighed in on the stock. Wall Street Zen upgraded shares of Palisade Bio from a "sell" rating to a "hold" rating in a report on Saturday, February 28th. Clear Str raised Palisade Bio to a "strong-buy" rating in a report on Monday, December 29th. Piper Sandler assumed coverage on Palisade Bio in a research note on Monday, December 29th. They issued an "overweight" rating and a $25.00 price objective for the company. Weiss Ratings restated a "sell (e+)" rating on shares of Palisade Bio in a report on Thursday, January 22nd. Finally, HC Wainwright began coverage on Palisade Bio in a research report on Thursday, March 26th. They set a "buy" rating and a $7.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $10.20.

Palisade Bio Trading Down 2.1%

Palisade Bio stock opened at $1.87 on Thursday. Palisade Bio has a 1-year low of $0.53 and a 1-year high of $2.64. The firm has a market capitalization of $310.20 million, a price-to-earnings ratio of -0.88 and a beta of 1.36. The firm's fifty day moving average price is $1.80 and its two-hundred day moving average price is $1.82.

Institutional Investors Weigh In On Palisade Bio

Several large investors have recently made changes to their positions in the business. Cetera Investment Advisers bought a new position in Palisade Bio during the fourth quarter valued at about $25,000. Schonfeld Strategic Advisors LLC purchased a new position in Palisade Bio in the fourth quarter valued at about $26,000. Virtu Financial LLC bought a new position in shares of Palisade Bio during the 4th quarter valued at approximately $28,000. Atom Investors LP bought a new position in shares of Palisade Bio during the 4th quarter valued at approximately $33,000. Finally, Barclays PLC purchased a new stake in shares of Palisade Bio during the 4th quarter worth approximately $35,000. 11.79% of the stock is owned by hedge funds and other institutional investors.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.